March 16, 2023

Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields) as well as to encourage… Read More
learn more
March 1, 2023

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

Optune is now available as a treatment for newly diagnosed glioblastoma patients in France ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering… Read More
learn more
March 1, 2023

Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

Final data from the METIS study anticipated in 2024 ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patients with… Read More
learn more
February 23, 2023

Allyson J. Ocean, M.D., Joins Novocure Board of Directors

Dr. Ocean, a medical oncologist and Associate Professor of Clinical Medicine at Weill Cornell Medicine, brings decades of experience in oncology to Novocure ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors. “We are honored… Read More
learn more
February 23, 2023

Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of pivotal PANOVA-3 study in pancreatic… Read More
learn more
February 15, 2023

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Final data from the PANOVA-3 study anticipated in 2024 ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of patients… Read More
learn more
January 19, 2023

Novocure Announces Organizational Changes to Prepare for Future Growth

ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17. Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new executive role as Chief Growth Officer. In this role, Mr. Shah will have worldwide responsibilities for product and portfolio strategy, brand… Read More
learn more
January 9, 2023

Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update

Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival Novocure announces first patients treated with new arrays Novocure to present… Read More
learn more
January 5, 2023

Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical congress ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically… Read More
learn more
December 27, 2022

Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference

ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on January 10, 2023. Mr. Read More
learn more